Menu
Search
|

Menu

Close
X

Zealand Pharma A/S ZEAL.OQ (NASDAQ Stock Exchange Global Select Market)

24.87 USD
+0.59 (+2.43%)
As of Sep 17
Previous Close 24.28
Open 24.57
Volume 167
3m Avg Volume 4,394
Today’s High 24.87
Today’s Low 24.57
52 Week High 24.87
52 Week Low 11.30
Shares Outstanding (mil) 31.81
Market Capitalization (mil) 4,937.65
Forward P/E 8.67
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.78 Mean rating from 9 analysts

KEY STATS

Revenue (mm, DKK)
FY19
0
FY18
38
FY17
136
FY16
231
EPS (DKK)
FY19
-4.134
FY18
18.871
FY17
-9.713
FY16
-6.711
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
8.67
33.85
Price to Sales (TTM)
vs sector
174.75
7.90
Price to Book (MRQ)
vs sector
4.52
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.55
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
67.31
12.69
Return on Equity (TTM)
vs sector
73.16
17.13

EXECUTIVE LEADERSHIP

Alf Nicklasson
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Emmanuel Dulac
Chief Executive Officer, Since 2019
Salary: --
Bonus: --
Kirsten Drejer
Independent Vice Chairman of the Board, Since 2019
Salary: --
Bonus: --
Ivan Moeller
Senior Vice President, Technical Development & Operations, Since 2018
Salary: --
Bonus: --
Andrew Parker
Executive Vice President, Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Smedeland 36
GLOSTRUP     2600

Phone:

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

SPONSORED STORIES